Wrap Text
Broad-Based Black Economic Empowerment Act: Annual Compliance Report
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", or the "Company", or the "Group")
28 June 2022
BROAD-BASED BLACK ECONOMIC EMPOWERMENT ACT: ANNUAL COMPLIANCE REPORT
In accordance with the JSE Limited Listings Requirements, notice is hereby given that the Company's
annual broad-based black economic empowerment compliance report ("compliance report") in terms
of section 13G (2) of the South African Broad-Based Black Economic Empowerment Act, No. 53 of
2003, as amended (the "B-BBEE Act"), has been submitted to the Broad-Based Black Economic
Empowerment Commission (the "B-BBEE Commission"). The compliance report is available on
Mediclinic's website at https://www.mediclinic.com/en/sustainable-development.html.
The compliance report relates to the Group's South African operations and presents an assessment of
the broad-based black economic empowerment status of Mediclinic International (RF) (Pty) Ltd, a
wholly owned subsidiary of the Company, and its subsidiaries which include Mediclinic Southern Africa
(Pty) Ltd.
About the B-BBEE Act
The B-BBEE Act was enacted to establish a legislative framework for the promotion of broad-based
black economic empowerment in South Africa. It covers aspects such as ownership, management
control, skills development, enterprise and supplier development and socio-economic development.
Although compliance with the B-BBEE Act and the Codes of Good Practice issued in terms thereof is
voluntary, an obligation was introduced by way of an amendment to the B-BBEE Act in 2013, which
became effective in June 2016, requiring a public company, listed on the Johannesburg Stock
Exchange ("JSE"), to submit its annual compliance report to the B-BBEE Commission, to load its
compliance report on its website and to publish a SENS announcement confirming the aforementioned
steps taken.
About Mediclinic International plc
Mediclinic is a diversified international private healthcare services group, established in South Africa in
1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the Middle East.
The Group's core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum
of care in such a way that the Group will be regarded as the most respected and trusted provider of
healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of
its markets.
At 31 March 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health
facilities, 20 day case clinics and 20 outpatient clinics. The Swiss operations included 17 hospitals and
four day case clinics with around 1 900 inpatient beds; Southern Africa operations included 50 hospitals
(three of which in Namibia), five subacute hospitals, two mental health facilities and 14 day case clinics
(four of which operated by Intercare) across South Africa, and around 8 650 inpatient beds; and the
Middle East operated seven hospitals, two day case clinics and 20 outpatient clinics with around 1 000
inpatient beds in the UAE. In addition, under management contract the Middle East will open a 200-bed
hospital in the Kingdom of Saudi Arabia in 2023.
The Company's primary listing is on the London Stock Exchange ('LSE') in the UK, with secondary
listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group
based in the UK and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)333 300 1930
Investor queries
James Arnold, Head of Investor Relations, Mediclinic International plc
+44 (0)20 3786 8181
ir@mediclinic.com
Media queries
FTI Consulting
Ben Atwell/Ciara Martin - UK
+44 (0)20 3727 1000
Sherryn Schooling - South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, UK
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
Date: 28-06-2022 04:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
